Allergan’s executive team orchestrates a $200M buyout to beef up gastroenterology pipeline
Allergan CEO Brent Saunders has bagged the latest in a long string of new biotech buyouts. The target this time: a diabetic gastroparesis drug …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
